LncRNA-DHC 在肝癌中的表达及临床意义
| 作者: |
1王李理,
1陶其飞,
1杨远,
1袁声贤
1 中国人民解放军海军军医大学附属东方肝胆外科医院肝外三科，上海 200438 |
| 通讯: |
袁声贤
Email: yuanshengx@126.com |
| DOI: | 10.3978/j.issn.2095-6959.2019.05.005 |
摘要
目的：研究lncR NA-DHC在肝癌中的表达及其对增殖及侵袭的影响和临床意义。方法：收集85例于中国人民解放军海军军医大学第三附属医院切除的肝癌组织，采用实时荧光定量PCR(quantitative real-time polymerase chain reaction，qRT-PCR)测定lncRNA-DHC在肝癌组织中的表达，并将其分成lncRNA-DHC高表达组和lncRNA-DHC低表达组，卡方检验分析lncRNA-DHC的表达与临床病理因素的关系，Kaplan-Meier生存曲线分析lncRNA-DHC的表达与肝癌患者无瘤生存和总生存时间的关系，采用Cox回归模型进行单因素和多因素风险因素分析。采用慢病毒转染SMMC7721和LM3细胞系，分为沉默表达组(KD组)与阴性对照组(Con组)，CCK-8测定KD组和Con组细胞增殖能力，Transwell实验测定两组侵袭能力。结果：LncRNA-DHC在肝癌组织中的相对表达量低于癌旁组织(1.73±1.31 vs 3.45±1.62，P<0.05)。LncRNA-DHC的表达与肝硬化(P=0.017)、微血管侵犯(P=0.034)相关。LncRNA-DHC低表达组1，3年无瘤生存率低于LncRNA-DHC高表达组，分别为42.1% vs 79.5%(P<0.01)与35.6% vs 67.6%(P<0.01)；lncRNA-DHC低表达组1，3年总生存率低于lncRNA-DHC高表达组，分别为70.3% vs 92.5%(P<0.01)与58.2% vs 83.4%(P<0.01)。肿瘤大小(P=0.002)、子灶(P<0.001)、lncRNA-DHC低表达(P=0.043)为影响无瘤生存的独立危险因素，肿瘤大小(P=0.001)、微血管侵犯(P=0.028)为影响总生存时间的独立危险因素。Con组OD450 nm值显著低于KD组(P<0.05)。Con组侵袭细胞数少于KD组(30±5 vs 90±20；P<0.05)。结论：LncRNA-DHC在肝细胞癌中低表达，且与恶性临床病理特征及预后差相关，lncRNA-DHC低表达为影响肝细胞癌患者无瘤生存的独立危险因素，沉默lncRNA-DHC的表达可促进肝细胞癌细胞增殖和侵袭。
关键词：
肝细胞癌；lncRNA-DHC；临床意义
Expression of long non-coding RNA-DHC in hepatocellular carcinoma and its clinical significance
CorrespondingAuthor: YUAN Shengxian Email: yuanshengx@126.com
DOI: 10.3978/j.issn.2095-6959.2019.05.005
Abstract
Objective: To investigate the expression of lncRNA-DHC in hepatocellular carcinoma, and analyze its effect on proliferation, migration and clinical significance. Methods: A total of 85 patients with hepatocellular carcinoma were selected. The expression of lncRNA-DHC in tumor tissues was measured by reverse transcription-quantitative polymerase chain reaction (qRT-PCR). The 85 cases was divided into a lncRNA-DHC over-expression group and a low-expression group. Chi-square test was used to test the association between these two groups with clinicopathological characteristics. The relationship between disease-free survival time and overall survival time with expression of lncRNA-DHC was measured by Kaplan-Meier method. Univariate and multivariate analyses was used by a Cox proportional hazards model. SMMC7721 and LM3 cell lines was transfect with Lentiviral, which was divided into a lncRNA-DHC silencing group (KD group) and a negative control group (Con group). The proliferation ability was test by CCK-8 assay. The invasion ability was measured by Transwell assay. Results: The expression of lncRNA-DHC in hepatocellular carcinoma tissue was significantly lower than that in adjacent normal tissues (1.73±1.31 vs 3.45±1.62, P<0.05). The expression of lncRNA-DHC was associated with cirrhosis (P=0.017), microvascular invasion (P=0.034). The 1, 3 years disease-free survival rate of the lncRNA-DHC low-expression group was significantly lower than that of the lncRNA-DHC over-expression group (42.1% vs 79.5%, P<0.01; 35.6% vs 67.6%, P<0.01, respectively). The 1, 3 years overall survival rate of the lncRNA-DHC low-expression group was significantly lower than that of the lncRNA-DHC over-expression group (70.3% vs 92.5%, P<0.01; 58.2% vs 83.4%, P<0.01, respectively). Tumor size (P=0.002), satellite (P<0.001) and lncRNA-DHC low-expression (P=0.043) were independent risk factors of disease-free survival. While, tumor size (P=0.002) and microvascular invasion (P=0.028) were independent risk factors of overall survival. The OD450 nm value of the Con group was significantly lower than that in the KD group (P<0.05). The invasive cell number of the Con group was significantly less than that in the KD group (30±5 vs 90±20, P<0.05). Conclusion: LncRNA-DHC is down-regulated expression in hepatocellular carcinoma, which is associated with malignant pathological features and poor prognosis. LncRNA-DHC low-expression is independent risk factor of disease-free survival. Silencing lncRNA-DHC expression can promote the proliferation and invasion.
Keywords：
hepatocellular carcinoma; lncRNA-DHC; clinical significance